November 29, 2014 12:24 AM ET

Pharmaceuticals

Company Overview of Iroko Pharmaceuticals Inc.

Company Overview

Iroko Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the development and commercialization of nonsteroidal anti-inflammatory drug therapeutics for patients to moderate acute and chronic pain. It provides Indocin for the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute painful shoulder, and acute gouty arthritis; and Aldomet to treat hypertension. The company’s products under development include Zorvolex, a formulation of diclofenac to treat acute pain in adult patients, as well as completed the Phase III clinical trials for the treatment of osteoarthritis pain; Tiforbex, a formulation of indomethacin that has completed the Phase III clini...

One Kew Place

150 Rouse Boulevard

Philadelphia, PA 19112

United States

Founded in 2012

71 Employees

Phone:

267-546-3003

Fax:

267-546-3004

Key Executives for Iroko Pharmaceuticals Inc.

Chief Executive Officer and President
Executive Chairman of the Board
Age: 52
Chief Financial Officer and Principal Accounting Officer
Age: 67
Senior Vice President
Age: 47
Senior Vice President and Chief Medical Officer
Age: 58
Compensation as of Fiscal Year 2014.

Iroko Pharmaceuticals Inc. Key Developments

Iroko Pharmaceuticals Inc. Announces New Strategic Agreement to Commercialize ZORVOLEX in Australia and New Zealand

Iroko Pharmaceuticals, LLC announced that its affiliate, Iroko Pharmaceuticals Inc., signed a licensing agreement with Aspen Pharma Pty Ltd. for the exclusive rights to register and market ZORVOLEX (diclofenac) capsules in Australia and New Zealand. Aspen Pharma Pty Ltd. will be responsible for obtaining regulatory and pricing approval, as well as the marketing and distribution of the medication.

Iroko Pharmaceuticals Inc. Signs New Strategic Agreement with Landsteiner Scientific, S.A. de C.V to Bring ZORVOLEX(R) to Mexico

Iroko Pharmaceuticals Inc. signed a licensing agreement with Landsteiner Scientific, S.A. de C.V., for the exclusive rights to market and sell ZORVOLEX(R) (diclofenac) capsules in Mexico. Landsteiner Scientific will be responsible for obtaining regulatory and pricing approval, as well as the marketing and distribution of the medication. ZORVOLEX is approved by the United States Food and Drug Administration (FDA) for the management of mild to moderate acute pain and osteoarthritis pain. ZORVOLEX is not currently approved for marketing in any other country. Iroko will continue to retain all marketing rights to ZORVOLEX in the U.S.

Iroko Pharmaceuticals Signs License Agreement with CALOX DE COSTA RICA S.A

Iroko Pharmaceuticals Inc. has signed a licensing agreement with CALOX DE COSTA RICA S.A. for the exclusive rights to market and sell Iroko's ZORVOLEX (diclofenac) capsules in specified countries in Latin America. Both the partners are pharmaceutical companies based in the US and Costa Rica respectively. CALOX will be responsible for obtaining regulatory and pricing approval, as well as the marketing and supply of the medication, in countries including Colombia, Costa Rica, Dominican Republic, El Salvador, Guatemala, Nicaragua, Honduras, Panama and Venezuela. ZORVOLEX was approved by the US Food and Drug Administration (FDA) in October 2013 for the treatment of mild to moderate acute pain in adults and is now available by prescription. ZORVOLEX is not currently approved for marketing in any other country. Iroko will continue to retain all marketing rights to ZORVOLEX in the US.

Similar Private Companies By Industry

Company Name Region
Southern Medical Renal Nutrition, Inc. United States
Life Force International Corporation United States
Perrigo Holland, Inc. United States
AstraZeneca Pharmaceuticals LP United States
Intermax Pharmaceuticals Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Iroko Pharmaceuticals Inc., please visit www.iroko.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.